WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) will unveil and demonstrate Quell, a novel wearable pain relief device at the 2015 International Consumer Electronics show (CES) January 6-9 in Las Vegas. Attendees will get their first glimpse of Quell at Booth # 73311 in the Digital Health section of CES. NeuroMetrix will also be one of an exclusive group that will participate in CES Unveiled, the official press event of CES.
Quell utilizes NeuroMetrix’s proprietary non-invasive neurostimulation technology to provide relief from chronic pain, such as due to diabetes, sciatica, fibromyalgia, and degenerative knee conditions. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy. The Company expects Quell to be available for purchase by consumers in the second quarter of 2015.
The Company also reported that Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer will participate in a CES Digital Health Summit panel entitled “Winning the War on Diabetes.” The panel discussion will be held on January 8, 2015 at 1:15pm. Dr. Gozani commented “Recent studies have shown that chronic nerve pain dramatically reduces the quality of life of people with diabetes. We believe that Quell may help many of these people reclaim their life from chronic pain.”
In addition to Dr. Gozani, the Company will be represented by Frank McGillin, SVP and General Manager Consumer, as well as members of the Company’s product development and marketing teams.
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit http://www.NeuroMetrix.com.